BMS ties with Janssen on Factor XIa inhibitor programme
Bristol-Myers Squibb and Johnson & Johnson group Janssen have announced a deal to work together on a Factor XIa (FXIa) inhibitor programme.
Read More
Tag: Factor XIa
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
